Halozyme Therapeutics Inc

8. Okt. 2026, 20:07 UTC

Halozyme Therapeutics received price target increases from JPMorgan to $78 and HC Wainwright to $130, while winning a patent case against Merck in the Netherlands.

7. Okt. 2026, 20:07 UTC

Halozyme Therapeutics shares advanced after a Dutch court ruling found Merck infringed on its MDASE patent, halting Keytruda SC sales in several European countries.

6. Okt. 2026, 19:45 UTC

Halozyme Therapeutics Inc is trading higher, with its cumulative return peaking earlier in the day while settling at a lower level within its one-month trading range.

2. Okt. 2026, 20:07 UTC

Halozyme Therapeutics Inc is advancing, continuing a higher trend since Thursday's close amid a broader market increase, contrasting with the previous five sessions.

1. Okt. 2026, 20:02 UTC

Halozyme Therapeutics Inc shares fell sharply, diverging from a recent trend of higher daily closes amid unusually high trading volume.

29. Sept. 2026, 20:07 UTC

Halozyme Therapeutics Inc shares fell sharply, marking a fourth consecutive lower daily close, despite remaining above its 20-day moving average.

25. Sept. 2026, 19:55 UTC

Halozyme Therapeutics Inc shares fell, despite a strong performance backdrop, remaining above the 20-day moving average and near the upper end of its one-month trading range.

24. Sept. 2026, 23:11 UTC

Halozyme Therapeutics Inc is trading modestly higher in after-market hours, remaining above its 20-day moving average and near the upper end of its one-month range.

23. Sept. 2026, 20:07 UTC

Halozyme Therapeutics Inc shares fell sharply after reaching a 52-week high, facing volatility and a decline during Wednesday's trading session.

22. Sept. 2026, 20:02 UTC

Halozyme Therapeutics Inc shares are rising as the company announced a $1.05 billion offering of convertible senior notes to enhance financial flexibility.

21. Sept. 2026, 20:06 UTC

Halozyme Therapeutics Inc shares fell as the company announced a proposed offering of $1.05 billion in convertible senior notes to extend debt maturity.

18. Sept. 2026, 20:06 UTC

Halozyme Therapeutics priced an upsized $1.3 billion offering of convertible senior notes, with shares trading higher amid strong session momentum.

17. Sept. 2026, 20:07 UTC

Halozyme Therapeutics announced a $1.05 billion convertible senior notes offering due in 2033, with shares trading higher amid strong performance metrics.

16. Sept. 2026, 23:01 UTC

Halozyme Therapeutics announced a proposed $1.05 billion offering of convertible senior notes, contributing to a decline in after-market trading.

15. Sept. 2026, 22:06 UTC

Halozyme Therapeutics Inc. shares were near unchanged in after-market hours, trading within a narrow range and below their 20-day moving average.

9. Sept. 2026, 20:07 UTC

Halozyme Therapeutics Inc is declining during Wednesday's session, continuing a trend lower since Tuesday. The stock remains above its 20-day moving average.

8. Sept. 2026, 19:26 UTC

Halozyme Therapeutics is trading lower, reflecting weakness after reaching a session high earlier. The stock remains down since Friday's close.

2. Sept. 2026, 20:08 UTC

HC Wainwright reiterated its Buy rating on Halozyme Therapeutics, maintaining a $115 price target as shares trade higher amid upcoming investor conference participation.

1. Sept. 2026, 20:08 UTC

Halozyme Therapeutics is rising today, driven by broader strength in biotechnology stocks. The stock remains near the upper end of its one-month range.

28. Aug. 2026, 20:08 UTC

Halozyme Therapeutics Inc shares declined Friday, reversing earlier gains amid rising U.S. Treasury yields and inflation concerns, with no specific news identified.

27. Aug. 2026, 19:16 UTC

Shares of Halozyme Therapeutics are lower during Thursday's session, reaching a low earlier. The stock remains above its 20-day moving average.

26. Aug. 2026, 23:46 UTC

Halozyme Therapeutics Inc. shares are higher in after-market trading, continuing gains since Wednesday's close and showing a strong month-over-month performance.

25. Aug. 2026, 19:36 UTC

Halozyme Therapeutics Inc is gaining during Tuesday's session, despite earlier trading lower. Broader market sentiment remains positive amid declining crude oil prices.

24. Aug. 2026, 23:36 UTC

Halozyme Therapeutics Inc shares are lower in after-market hours. Broader market concerns over geopolitical tensions are impacting investor confidence.

21. Aug. 2026, 19:36 UTC

Halozyme Therapeutics Inc is trading higher, continuing its upward trend since Thursday's close. No specific news was identified to explain the movement.

20. Aug. 2026, 20:06 UTC

Halozyme Therapeutics shares are lower amid concerns over recent insider selling by CEO Helen Torley, who sold $2.13 million in stock.

19. Aug. 2026, 19:56 UTC

Halozyme Therapeutics shares are higher as investor confidence grows following the election of Dannielle Appelhans to its Board of Directors.

18. Aug. 2026, 23:41 UTC

Halozyme shares are lower in after-market trading following the announcement of Dannielle Appelhans' election to the Board of Directors, effective August 2026.

17. Aug. 2026, 23:02 UTC

Halozyme Therapeutics shares are higher in after-market hours, recovering from earlier session declines and remaining near the upper end of their one-month trading range.

14. Aug. 2026, 20:06 UTC

Halozyme Therapeutics Inc shares are lower amid broader market concerns following a decline in U.S. retail sales, continuing a trend of volatility.